ReviewCurrent hematologic malignancy reports2016
T-cell Lymphoma Epidemiology: the Known and Unknown.
Review in Current hematologic malignancy reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma.Cancer science · 2021Trial
- Review
- Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study.Cell communication and signaling : CCS · 2025Article
- Treatment patterns and survival outcomes of peripheral T-Cell lymphoma in Saudi Arabia: a 12-Year retrospective analysis.BMC cancer · 2025Article
- Immunohistochemical Subclassification of Peripheral T Cell Lymphomas-Not Otherwise Specified.South Asian journal of cancer · 2025Article
- Evans Blue Acts as a Selective Inhibitor of CaMKII-α to Impede the Progression of TCL Identified by HTS.Cancer science · 2025Article
- Perspectives on the Mature T-Cell Lymphomas in the Middle East: A Comprehensive Review of the Present Status.Cancers · 2024Review
- Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study in China.Italian journal of pediatrics · 2024Article
- Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.International journal of hematology · 2024Article
- Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas.Leukemia research reports · 2024Article
- Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy.Genes & diseases · 2024Review
- Article
- Diffuse Large B-Cell lymphoma Misdiagnosed as a Hematoma: Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Unusual Presentation ofInternational journal of molecular sciences · 2023Article
- [Management of pruritus in the elderly].Dermatologie (Heidelberg, Germany) · 2023Review
- Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma.Clinical and experimental medicine · 2023Article
- Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.Cancer research and treatment · 2023Article
- Autophagy in Hematological Malignancies.Cancers · 2022Review
- Article
- The Role of Epstein-Barr Virus in Modulating Key Tumor Suppressor Genes in Associated Malignancies: Epigenetics, Transcriptional, and Post-Translational Modifications.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell lymphoma, a collection of subtypes of Non-Hodgkin lymphoma, is a rare malignancy. The low prevalence of this disease has made it challenging to identify subtype-specific risk factors. Potential risk factors could enable us to identify high-risk patients and predict patient outcomes. Here, we report on the current epidemiologic and prognostic factors data associated with the individual subtypes both of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) found in large cohort and case studies. Additionally, with recent findings, as well as updates in the new World Health Organization (WHO) classification of lymphoid neoplasms, we consider what this could do to change our approach to this group of diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.